AstraZeneca PLC Ownership
| AZN Stock | USD 67.62 0.42 0.63% |
Shares in Circulation | First Issued 1993-03-31 | Previous Quarter 3.1 B | Current Value 3.1 B | Avarage Shares Outstanding 2.7 B | Quarterly Volatility 541.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
AstraZeneca |
AstraZeneca Stock Ownership Analysis
About 17.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.73. AstraZeneca PLC ADR last dividend was issued on the 9th of August 2024. The entity had 2:1 split on the 27th of July 2015. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 83100 people. For more info on AstraZeneca PLC ADR please contact Pascal Soriot at 44 20 3749 5000 or go to https://www.astrazeneca.com.Besides selling stocks to institutional investors, AstraZeneca PLC also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AstraZeneca PLC's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AstraZeneca PLC's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AstraZeneca PLC Quarterly Liabilities And Stockholders Equity |
|
AstraZeneca Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AstraZeneca PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AstraZeneca PLC ADR backward and forwards among themselves. AstraZeneca PLC's institutional investor refers to the entity that pools money to purchase AstraZeneca PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fisher Asset Management, Llc | 2024-09-30 | 10.5 M | Atlantic Trust Group, Llc | 2024-06-30 | 9.2 M | Blackrock Inc | 2024-06-30 | 7 M | Capital World Investors | 2024-09-30 | 6.3 M | Gqg Partners Llc | 2024-09-30 | 5.5 M | Neuberger Berman Group Llc | 2024-06-30 | 5.4 M | Ing Investment Management Llc | 2024-06-30 | 5.3 M | Ameriprise Financial Inc | 2024-06-30 | 4.9 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 4.7 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 64.9 M | Primecap Management Company | 2024-09-30 | 42 M |
AstraZeneca PLC's latest congressional trading
Congressional trading in companies like AstraZeneca PLC ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in AstraZeneca PLC by those in governmental positions are based on the same information available to the general public.
| 2021-12-14 | Representative Alan S Lowenthal | Acquired Under $15K | Verify | ||
| 2021-08-13 | Representative Dean Phillips | Acquired Under $15K | Verify | ||
| 2021-03-05 | Representative Alan S Lowenthal | Acquired $1,001 - | Verify | ||
| 2020-12-23 | Representative Greg Gianforte | Acquired Under $15K | Verify |
AstraZeneca PLC Outstanding Bonds
AstraZeneca PLC issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AstraZeneca PLC ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AstraZeneca bonds can be classified according to their maturity, which is the date when AstraZeneca PLC ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ASTRAZENECA PLC 645 Corp BondUS046353AD01 | View | |
| ASTRAZENECA PLC 3375 Corp BondUS046353AL27 | View | |
| ASTRAZENECA PLC 4375 Corp BondUS046353AM00 | View | |
| ASTRAZENECA PLC 4 Corp BondUS046353AG32 | View | |
| ASTRAZENECA PLC 4 Corp BondUS046353AT52 | View | |
| ASTRAZENECA PLC 4375 Corp BondUS046353AU26 | View | |
| ASTRAZENECA PLC 3125 Corp BondUS046353AN82 | View | |
| ASTRAZENECA PLC Corp BondUS046353AV09 | View |
AstraZeneca PLC Corporate Filings
6K | 25th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 28th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
| 0.78 | HLN | Haleon plc | PairCorr |
| 0.9 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.81 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.81 | ANRO | Alto Neuroscience, | PairCorr |
Moving against AstraZeneca Stock
| 0.83 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.78 | FNMFO | Federal National Mortgage | PairCorr |
| 0.77 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.47 | ITCL | Banco Ita Chile | PairCorr |
| 0.44 | KB | KB Financial Group | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.034 | Dividend Share 2.97 | Earnings Share 2.08 | Revenue Per Share 2.7424 | Quarterly Revenue Growth 0.18 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.